ASP Isotopes (ASPI) Q3 2025 earnings summary

Executive summary

• Operational enrichment plants in South Africa are producing and shipping commercial samples of silicon-28 and ytterbium-176, with customer validation and the largest silicon-28 contract secured for 2026 delivery.

• Acquisition of Renergen is nearing completion, pending final regulatory approval, with phase 1C focused on LNG and helium production and free cash flow expected in 2026.

• Expansion into the U.S. market includes the purchase of East Coast Nuclear, a second radiopharmacy under term sheet, and due diligence on further acquisitions.

• Quantum Leap Energy (QLE) is advancing modular nuclear waste treatment and enrichment, raising $64.3 million via convertible note, acquiring a nuclear waste processing company, and planning a spin-out IPO in Q4 2025.

• Strategic acquisitions, including Skyline Builders and Supercritical, aim to secure critical material supply chains, enable vertical integration, and expand into construction services.

Financial highlights

• Q3 2025 revenue reached $8.3 million, up from $7.9 million in Q2 2025 and $1.2 million in Q3 2024; nine-month revenue was $7.2 million, driven by Skyline acquisition.

• Excluding Skyline, Q3 2025 radiopharmaceutical revenues were $1.3 million, up 18% year-over-year; year-to-date radiopharmaceutical revenues reached $3.6 million, up 24%.

• Year-to-date operating expenses rose 84% to $36.2 million, with Q3 2025 operating expenses at $15.4 million, up from $12.5 million in Q2 2025.

• Net loss for the nine months ended September 30, 2025 was $96.5 million, compared to $23.2 million in the prior year period.

• Cash balance as of September 30, 2025, was $113.9 million, with an additional $200 million raised subsequently.

Outlook and guidance

• No change to prior revenue guidance of $50–$70 million in 2026–2027 for Ytterbium-176 and Silicon-28; further updates pending completion of corporate events.

• Initial commercial revenue from carbon expected by year-end, with silicon revenue to follow in early 2026; ongoing supply contracts extend through 2026.

• Construction of new isotope enrichment plants planned in Iceland, the U.S., and the U.K. during 2026, with additional radiopharmaceutical expansion.

• IPO of Quantum Leap Energy targeted for Q4 2025, with S-1 filed confidentially.

• Management expects existing cash and recent financings to fund operations for more than 12 months from the financial statement issuance date.